These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 28785006

  • 21. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
    Kull S, Schulz KM, Weisemann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dorner MB, Barr JR, Rummel A, Dorner BG.
    PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
    [Abstract] [Full Text] [Related]

  • 22. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.
    Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T.
    Biochem J; 2013 Jul 01; 453(1):37-47. PubMed ID: 23621114
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins.
    Lam KH, Tremblay JM, Vazquez-Cintron E, Perry K, Ondeck C, Webb RP, McNutt PM, Shoemaker CB, Jin R.
    Cell Rep; 2020 Feb 25; 30(8):2526-2539.e6. PubMed ID: 32101733
    [Abstract] [Full Text] [Related]

  • 31. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).
    Bakherad H, Mousavi Gargari SL, Rasooli I, Rajabibazl M, Mohammadi M, Ebrahimizadeh W, Safaee Ardakani L, Zare H.
    Mol Biotechnol; 2013 Oct 25; 55(2):159-67. PubMed ID: 23666874
    [Abstract] [Full Text] [Related]

  • 32. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV, Aoki KR, Atassi MZ.
    Infect Immun; 2015 Apr 25; 83(4):1465-76. PubMed ID: 25624352
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.
    Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R.
    Clin Vaccine Immunol; 2013 Aug 25; 20(8):1266-73. PubMed ID: 23761665
    [Abstract] [Full Text] [Related]

  • 36. A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different Subtypes.
    Gregory KS, Acharya KR.
    Toxins (Basel); 2023 Jan 18; 15(2):. PubMed ID: 36828407
    [Abstract] [Full Text] [Related]

  • 37. Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.
    Liu Z, Lee PG, Krez N, Lam KH, Liu H, Przykopanski A, Chen P, Yao G, Zhang S, Tremblay JM, Perry K, Shoemaker CB, Rummel A, Dong M, Jin R.
    Nat Commun; 2023 Apr 24; 14(1):2338. PubMed ID: 37095076
    [Abstract] [Full Text] [Related]

  • 38. Structure of the BoNT/A1--receptor complex.
    Benoit RM, Frey D, Wieser MM, Thieltges KM, Jaussi R, Capitani G, Kammerer RA.
    Toxicon; 2015 Dec 01; 107(Pt A):25-31. PubMed ID: 26260692
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.